Scientific deep-dive

GLP-1 Drugs and Headache: A Side Effect, and a Treatment

Headache is in the label’s adverse reactions table at 14% against 10% on placebo. A randomized trial using implanted pressure monitors also found a GLP-1 lowered intracranial pressure within hours.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·4 citations

These drugs cause headaches and are being studied as a treatment for one. The Wegovy label reports headache in 14% of patients against 10% on placebo.[4] Meanwhile a randomized trial using pressure monitors implanted in the skull found a GLP-1 measurably lowered intracranial pressure in women with idiopathic intracranial hypertension, a condition whose defining symptom is headache.[1] A 2025 review titles this problem exactly: when these medications are therapeutic, and when they contribute to the symptom.[2]

The side effect, first

Headache sits in the adverse reactions table of the label, not in a warning section, which places it among the common and generally self-limiting effects rather than the dangerous ones. In the adult weight-management trials it was reported by 14% of people on Wegovy and 10% on placebo.[4] That gap is real and it is narrow: with 10% reporting headache on placebo, most of the headaches reported on the drug would probably have happened without it.

Dehydration is the mechanism to know about, because it is the one you can do something about. Nausea, vomiting and reduced fluid intake all follow from how these drugs work, and all of them cause headaches independently. Our water intake calculator works a target, and how long side effects last covers the early-weeks pattern most of them follow.

The condition where this gets interesting

Idiopathic intracranial hypertension is raised pressure around the brain with no tumor or clot to explain it. It causes severe headache and, because the pressure is transmitted to the optic nerve, it can take your sight. It can also cause a ringing in time with the heartbeat. It is strongly associated with obesity, and it predominantly affects women of childbearing age, a population that overlaps heavily with the one being prescribed these drugs for weight.

Weight loss has long been the most effective treatment, which made a weight-loss drug an obvious thing to test. What was not obvious is that GLP-1 receptor signaling might lower intracranial pressure directly, which is what the preclinical work suggested.[1]

What the trial did

The design is the impressive part. Rather than asking participants how their headaches felt, the researchers used telemetric catheters to monitor intracranial pressure continuously, giving an objective endpoint of a kind headache research rarely gets.[1] Adult women with active disease (pressure above 25 cmCSF and swelling of the optic disc) received exenatide or placebo, double-blind.

Change in intracranial pressure against placebo. Brain, 2023. 16 women recruited, 15 completed.
TimepointChange (cmCSF)P
2.5 hours−5.7 ± 2.90.048
24 hours−6.4 ± 2.90.030
12 weeks−5.6 ± 3.00.058

Participants averaged 28 years old, a BMI of 38.1, and a starting pressure of 30.6 cmCSF.[1] A drop of roughly 6 from that baseline is not cosmetic, and it happened within hours. That is faster than any weight change could explain, and it is the strongest argument that something other than weight loss is doing the work.

Two things belong beside those P values. Fifteen women completed the study. And the trial set its significance threshold a priori at 0.10 rather than the conventional 0.05. That is a defensible choice in a small early trial with an invasive endpoint, and one a reader should be told about. The two early results clear 0.05. The 12-week result (P = 0.058) clears only the trial’s own 0.10 bar, and that is part of how to weigh it.

Migraine is a weaker story, and worth separating

A 2024 systematic review searched the whole GLP-1-and-pain literature, screening 833 records down to 42 studies across inflammatory pain, headache, neuropathic pain and visceral pain.[3] What it found for headache specifically is mechanistic: GLP-1 appears to be involved in migraine biology, and GLP-1 drugs show analgesic effects in animal models of inflammatory and neuropathic pain.

That is a reason to run trials, and the first small human studies are reviewed in GLP-1s and migraine. It is not a reason to expect your migraines to improve, and the distinction matters because obesity and migraine are themselves linked. People with obesity who have migraine are at higher risk of it becoming chronic, so weight loss by any route may help without the drug doing anything to the migraine directly.[2]

For migraine, the evidence is mechanistic and largely in animal models. There is no evidence that a GLP-1 will ease yours.

If you get headaches on one of these

  • Fluids first. The gastrointestinal effects dehydrate people, dehydration causes headache, and this is the part within your control.
  • Tell your prescriber if it is new, severe, or different from your usual pattern. That is the standard advice for headache generally, and it is not weakened by being on a drug that lists headache.
  • Vision changes with headache are urgent. Blurring, transient graying-out, or double vision alongside headache is how raised intracranial pressure presents, and it is a same-day problem rather than a wait-and-see one.
  • Do not self-treat a headache disorder with a weight-loss drug. No GLP-1 is approved for any headache condition, and the IIH evidence is a 15-person trial.

For the separate question of what these drugs do to the eye, our NAION and retinopathy article covers the vision risks that have their own evidence base, and blurred vision on a GLP-1 sorts everyday blur by cause.

Frequently Asked Questions

Headache is listed in the label's adverse reactions table: it was reported by 14% of adults on Wegovy against 10% on placebo. It sits among the common, generally self-limiting effects rather than in a warning section. Dehydration from nausea, vomiting and reduced fluid intake is a mechanism worth addressing because it is the one you can act on.
It is being studied, and the early evidence is interesting. A randomized trial using implanted pressure monitors found exenatide lowered intracranial pressure by about 5.7 cmCSF at 2.5 hours, 6.4 at 24 hours and 5.6 at 12 weeks in women with active idiopathic intracranial hypertension. Fifteen women completed that study and it set its significance threshold at 0.10, so it is a starting point rather than a basis for treatment.
There is no evidence that it will. The migraine research is mechanistic and largely in animal models. Obesity and migraine are separately linked, so weight loss may help some people without the drug acting on migraine at all, which is a different claim.
That is the most intriguing part of the trial. The reduction appeared within 2.5 hours, far faster than any weight change could account for, which supports the preclinical suggestion that GLP-1 receptor signaling lowers intracranial pressure directly rather than through weight loss.
When it comes with vision changes (blurring, brief graying-out, or double vision). That combination is how raised intracranial pressure presents, and it needs same-day attention. A headache that is new, severe, or unlike your usual pattern also warrants contacting your prescriber.

References

  1. 1.Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial Brain. 2023. PMID: 36907221.
  2. 2.Ferreira ET, Garcia LMP, Londero RG. Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom Arquivos de Neuro-Psiquiatria. 2025. PMID: 41145149.
  3. 3.Halloum W, Dughem YA, Beier D, Pellesi L. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review The Journal of Headache and Pain. 2024. PMID: 38997662.
  4. 4.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Adverse Reactions (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Phentermine and a GLP-1 Together: What the Labels and Trials Show

Phentermine's label says combining it with any other weight-loss drug is not recommended; the Wegovy and Zepbound labels never mention it. The one trial, with liraglutide, found no meaningful extra loss. No semaglutide or tirzepatide trial exists.

10 min read

Metformin and a GLP-1 Together: The Risk Is Not the One People Expect

The diabetes trials behind these drugs were largely run on people already taking metformin. Stomach side effects did not stack in the largest analysis, and low blood sugar comes from other drugs. The real overlap is dehydration.

8 min read

Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off

Stopping Ozempic or Wegovy causes no withdrawal syndrome on either label. Appetite returns as semaglutide clears over about five weeks, and a 2026 BMJ meta-analysis found regain of about 0.8 kg a month. What helps keep weight off, and what women should know.

10 min read

Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist

The most detailed published evidence that GLP-1 drugs cause dry mouth is three case reports, alongside an adverse-event reporting signal for semaglutide. Nobody has measured how often it happens, but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.

5 min read

GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

7 min read

GLP-1 Drugs and Rheumatoid Arthritis: One Study, and What It Cannot Tell You

A retrospective review of 215 patients found greater falls in disease activity and pain among those who took a GLP-1 than among those prescribed one who did not. Nearly a third stopped the drug within the year.

6 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.2

Oak

A choice of compounded injections, oral semaglutide and brand-name GLP-1s from one cash-pay checkout

6.4

MyDrHank

An oral route if you will not self-inject

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →